NCT04344860View on ClinicalTrials.gov

Prevent Postpartum Hemorrhage in Women with Von Willebrand Disease: the VWD-WOMAN Trial

PHASE3CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 4, 2021

Primary Completion Date

August 28, 2024

Study Completion Date

September 1, 2024

Conditions
Von Willebrand DiseasesPostpartum Hemorrhage
Interventions
DRUG

Recombinant Von Willebrand factor

Recombinant Von Willebrand factor(Vonvendi) is an intravenous therapy that replaces missing VWF to restore hemostasis and reduce bleeding with surgery or delivery.

DRUG

Tranexamic Acid Injection [Cyklokapron]

Tranexamic acid (Cyclokapron) is an intravenous anti-fibrinolytic therapy that prevents clot breakdown and reduces bleeding with surgery or delivery.

Trial Locations (1)

15213

Hemophilia Center of Western PA, Pittsburgh

All Listed Sponsors
lead

Nicoletta C Machin

OTHER